Table 1 The clinic-pathologic characteristics of luminal B HER2-negative breast cancer

Age (years) median

48.5

55.5

0.0336

 = or <45

59 (36.9)

3 (12.5)

 >45

101 (62.1)

21 (87.5)

TNM stage (AJCC 8th)

0.1061

 I

50 (31.2)

5 (20.8)

 II

81 (50.6)

11 (45.8)

 III

27 (16.9)

6 (25.0)

 IV

2 (1.3)

2 (8.3)

Breast operation

0.8761

 BCS

113 (70.6)

16 (66.7)

 Mastectomy

47 (29.4)

8 (33.3)

Axillary node operation

0.2088

 SLNB

63 (39.4)

7 (29.2)

 ALND

96 (60.0)

16 (66.7)

 omit

1 (0.6)

1 (4.2)

Histologic type

0.1587

 Invasive ductal carcinoma

142 (88.8)

22 (91.7)

 Invasive Lobular carcinoma

5 (3.1)

2 (8.3)

 Mucinous carcinoma

6 (3.8)

0 (0)

 Papillary carcinoma

6 (3.8)

0 (0)

 Micropapillary carcinoma

3 (1.9)

0 (0)

 Apocrine carcinoma

1 (0.3)

0 (0)

Histologic grade

0.4421

 II

31 (19.4)

8 (33.3)

 III

101 (63.1)

16 (66.7)

 Not available

28 (17.5)

0 (0)

Nuclear grade

0.9403

 I

82 (51.2)

14 (58.3)

 II

45 (28.1)

9 (37.5)

 III

5 (3.1)

1 (4.2)

 Not available

28 (17.5)

0 (0)

Number of tumor

0.6269

 Single

137 (85.6)

22 (91.7)

 Multiple

23 (14.4)

2 (8.3)

Bcl-2 expression

0.0006

 = or <10 %

17 (10.9)

11 (39.3)

 >10 %

139 (89.1)

17 (60.7)

Ki 67

0.0167

 = or <50 %

136 (85.0)

15 (62.5)

 >50 %

24 (15.0)

9 (37.5)

  Yes

133 (83.1)

22 (91.7)

0.1321

  Anthracycline/taxane based

72 (45.0)

17 (70.8)

  CMF or CNF based

50 (36.9)

5 (20.7)

  No

27 (16.9)

2 (8.3)

  Yes

148 (92.5)

22 (91.7)

0.0579

  SERM

100 (62.5)

9 (37.5)

  AI

49 (30.6)

13 (54.2)

  No

11 (6.9)

2 (8.3)

  Yes

110 (68.7)

17 (70.8)

0.9752

  No

50 (31.2)

7 (29.2)